Empirical Finance LLC Decreases Position in IQVIA Holdings Inc. (NYSE:IQV)

Empirical Finance LLC lowered its position in shares of IQVIA Holdings Inc. (NYSE:IQV) by 1.2% in the 4th quarter, Holdings Channel.com reports. The fund owned 6,222 shares of the medical research company’s stock after selling 78 shares during the quarter. Empirical Finance LLC’s holdings in IQVIA were worth $1,223,000 as of its most recent SEC filing.

A number of other hedge funds also recently added to or reduced their stakes in IQV. FMR LLC increased its holdings in shares of IQVIA by 38.7% in the 3rd quarter. FMR LLC now owns 2,887,342 shares of the medical research company’s stock worth $684,213,000 after purchasing an additional 804,963 shares in the last quarter. JPMorgan Chase & Co. increased its holdings in IQVIA by 46.2% in the 3rd quarter. JPMorgan Chase & Co. now owns 1,845,711 shares of the medical research company’s stock worth $437,378,000 after buying an additional 583,396 shares in the last quarter. Impax Asset Management Group plc lifted its stake in IQVIA by 9.7% during the 3rd quarter. Impax Asset Management Group plc now owns 1,793,010 shares of the medical research company’s stock valued at $423,885,000 after acquiring an additional 157,809 shares during the period. Nordea Investment Management AB boosted its holdings in shares of IQVIA by 47.4% during the 4th quarter. Nordea Investment Management AB now owns 1,405,281 shares of the medical research company’s stock valued at $277,908,000 after acquiring an additional 452,029 shares during the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its stake in shares of IQVIA by 3.4% in the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 1,226,083 shares of the medical research company’s stock worth $290,545,000 after acquiring an additional 39,772 shares during the period. 89.62% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, Director John G. Danhakl acquired 1,275 shares of IQVIA stock in a transaction on Tuesday, December 3rd. The shares were acquired at an average price of $200.58 per share, with a total value of $255,739.50. Following the purchase, the director now directly owns 1,275 shares in the company, valued at $255,739.50. The trade was a ∞ increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 1.60% of the company’s stock.

IQVIA Stock Performance

NYSE:IQV opened at $206.67 on Tuesday. The stock has a 50-day moving average price of $200.67 and a 200 day moving average price of $219.27. The stock has a market capitalization of $37.51 billion, a P/E ratio of 27.56, a P/E/G ratio of 2.25 and a beta of 1.48. IQVIA Holdings Inc. has a 12-month low of $187.62 and a 12-month high of $261.73. The company has a current ratio of 0.84, a quick ratio of 0.81 and a debt-to-equity ratio of 2.12.

IQVIA (NYSE:IQV) last announced its quarterly earnings data on Thursday, February 6th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%. Equities research analysts forecast that IQVIA Holdings Inc. will post 10.81 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on the stock. Deutsche Bank Aktiengesellschaft dropped their target price on shares of IQVIA from $270.00 to $265.00 and set a “buy” rating on the stock in a report on Friday, November 1st. Stephens started coverage on IQVIA in a research note on Friday, December 20th. They issued an “overweight” rating and a $250.00 price target on the stock. TD Cowen lowered their target price on IQVIA from $270.00 to $255.00 and set a “buy” rating on the stock in a report on Friday, November 1st. Leerink Partners reissued an “outperform” rating and issued a $248.00 target price (down from $260.00) on shares of IQVIA in a research report on Tuesday, November 19th. Finally, StockNews.com cut shares of IQVIA from a “buy” rating to a “hold” rating in a research note on Thursday, November 28th. Five equities research analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $252.50.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.